An update on disordered iron metabolism and iron overload

Hematology

Volumn 15, Issue 5, 2010, Pages 311-317

  Ward, R ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

hepcidin; iron chelation; Iron overload; thalassemia

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; HEPCIDIN; SMAD PROTEIN; TRANSFERRIN;

ANOXIA; ARTHRALGIA; ARTHRITIS; BLOOD TRANSFUSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EYE TOXICITY; FANCONI RENOTUBULAR SYNDROME; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEART DISEASE; HEART VENTRICLE FUNCTION; HEMOCHROMATOSIS; HUMAN; ION TRANSPORT; IRON CHELATION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON METABOLISM DISORDER; IRON OVERLOAD; KIDNEY DISEASE; LOCAL SKIN REACTION; MONOTHERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OXYGEN TRANSPORT; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SURVIVAL TIME; TARGET ORGAN; THALASSEMIA MAJOR; ZINC DEFICIENCY;

ANIMALS; BLOOD TRANSFUSION; DEFEROXAMINE; DRUG THERAPY, COMBINATION; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; THALASSEMIA;

EID: 77957303144     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12647083621164     Document Type: Review

References (65)

1. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008;2008:151-158.
2. Hershko C Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998;850:191-201.
3. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006;2006:29-35.
4. Tanno T, Bhanu NV, Oneal PA et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-186.
5. Origa R, Galanello R, Ganz T et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92:583-588.
6. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;2:2.
7. Walter PB, Harmatz1 PR, Higa A et al. Iron overload diminishes the effectiveness of the innate immune response in thalassemia major: a possible mechanism for increased infection risk. ASH Annu Meet Abstr 2009;114:4071.
8. Melchiori L, Gardenghi S, Guy EC et al. Use of Jak2 inhibitors to limit ineffective erythropoiesis and iron absorption in mice affected by beta-thalassemia and other disorders of red cell production. ASH Annu Meet Abstr 2009;114:2020.
9. Gardenghi S, Marongiu MF, Ramos P et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and upregulation of ferroportin. Blood 2007;109:5027-5035.
10. Melis MA, Cau M, Congiu R et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008;93:1473-1479.
11. Ramsay AJ, Dong Y, Hunt ML et al. Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 2009;94:840-849.
12. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program 2006;2006:36-41.
13. Hoffbrand AV, Catovsky D, Tuddenham EG. Postgraduate haematology. 5th ed. Malden, MA: Blackwell Pub, 2005.
14. Gibert Y, Lattanzi VJ, Fraenkel PG. Knockdown of matriptase-2 increases hepcidin expression in a BMP-dependent manner in zebrafish embryos. ASH Annu Meet Abstr 2009;114:4050.
15. Létocart E, Le Gac G, Majore S et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009;147:379-385.
16. Lee MT, Piomelli S, Granger S et al. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood 2006;108:847-852.
17. Telfer PT, Prestcott E, Holden S et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000;110:971-977.
18. * magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120:1961-1968.
19. *) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
20. Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in ironoverloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004;104:1504-1510.
21. Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients. Eur J Haematol 2010;84:72-78.
22. Zanninelli G, Breuer W, Cabantchik ZI Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol 2009;147:744-751.
23. Piga A, Longo F, Duca L et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009;84:29-33.
24. Taher A, Musallam KM, El Rassi F et al. Levels of nontransferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009;146:569-572.
25. Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007;82(12 Suppl.):1128-1131.
26. Borgna-Pignatti C, Rugolotto S, de Stefano P et al. Survival and complications in thalassemia. Ann NY Acad Sci 2005;1054:40-47.
27. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187-1194.
28. Wood JC, Claster S, Carson S et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol 2008;141:891-894.
29. Noetzli LJ, Papudesi J, Coates TD et al. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009;114:4021-4026.
30. de Assis RA, Andreza AFP, Alexandre HC et al. Non-invasive assessment of pancreatic iron stores by magnetic resonance imaging (MRI) in beta-thalassemic patients. ASH Annu Meet Abstr 2009;114:4052.
31. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007;138:407-421.
32. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82(12 Suppl.):1136-1139.
33. Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007;47:1919-1929.
34. Porter JB, Jaswon MS, Huehns ER et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989;73:403-409.
35. Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol 1999;60:24-26.
36. Porter JB, Abeysinghe RD, Marshall L et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88:705-713.
37. Cappellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med 2008;8:663-674.
38. Roberts D, Brunskill S, Doree C, Williams S, Howard J, Hyde C. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007;(3):CD004839.
39. Cohen AR, Galanello R, Piga A et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;108:305-312.
40. Cohen AR, Galanello R, Piga A et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
41. Ceci A, Baiardi P, Felisi M et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336.
42. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 2008;141:882-890.
43. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107:3436-3441.
44. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009;11:20.
45. Borgna-Pignatti C, Cappellini MD, de Stefano P et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-3737.
46. Pennell DJ, Berdoukas V, Karagiorga M et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-3744.
47. Piga A, Gaglioti C, Fogliacco E et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-496.
48. ®) in patients with beta-thalassemia major treated for up to 5 years. ASH Annu Meet Abstr 2009;114:4063.
49. Daar S, Pathare A, Nick H et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009;82:454-457.
50. Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol 2008;83:398-402.
51. ®) in beta-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. ASH Annu Meet Abstr 2009;114:4062.
52. Smith G, Pennell DJ, Porter JB et al. Improvement in right ventricular function following 1 year of deferasirox therapy in patients with betathalassemia. ASH Annu Meet Abstr 2009;114:5106.
53. Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beat-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-465.
54. Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusiondependent anaemia and iron overload. Br J Haematol 2009;147:752-759.
55. Evans E, Kleinert, DA, Mennitt K et al. Iron chelation with deferasirox in thalassemia major patients with low iron burdens and moderate to high transfusion regimens. ASH Annu Meet Abstr 2009;114:4070.
56. Chirnomas D, Smith AL, Braunstein J et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009;114:4009-4013.
57. Garbowski MW, Fabre M, Evans P, Porter JB. Vitamin C status in transfusionally iron-overloaded patients on long-term deferasirox and its relationship to myocardial iron removal. ASH Annu Meet Abstr 2009;114:2005.
58. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
59. Mourad FH, Hoffbrand AV, Sheikh-Taha M et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-189.
60. Tanner MA, Galanello R, Dessi C et al. A randomized, placebocontrolled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884.
61. Maggio, Vitrano A, Capra M et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematology 2009;145:245-254.
62. Telfer PT, Warburton F, Christou S et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 2009;94:1777-1778.
63. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-475.
64. Lal A, Sweeters N, Herz M et al. Safety of combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia. ASH Annu Meet Abstr 2009;114:2021.
65. Nemeth E. Development of hepcidin agonists and antagonists. ASH Annu Meet Abstr 2009;114:SCI-27.